• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Circumventing resistance to kinase-inhibitor therapy.

作者信息

Druker Brian J

出版信息

N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.

DOI:10.1056/NEJMe068073
PMID:16775240
Abstract
摘要

相似文献

1
Circumventing resistance to kinase-inhibitor therapy.规避对激酶抑制剂疗法的耐药性。
N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.
2
As leukemia options grow, drugs jockey to be first-line therapies.随着白血病治疗选择的增加，各种药物竞相成为一线治疗方案。
Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7.
3
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.博舒替尼、达沙替尼和尼罗替尼对18种伊马替尼耐药的BCR/ABL突变体的活性。
J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15.
4
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.费城染色体阳性白血病患者对达沙替尼的耐药性以及BCR-ABL激酶结构域中315和317位残基处突变的存在或选择。
Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822.
5
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.韩国慢性髓性白血病患者在接受 Abl 酪氨酸激酶抑制剂治疗期间 T315I BCR-ABL 激酶结构域突变的动态变化。
Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.
6
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.慢性粒细胞白血病患者在接受酪氨酸激酶抑制剂治疗过程中BCR-ABL激酶结构域突变的复杂性
Am J Hematol. 2009 Apr;84(4):256-7. doi: 10.1002/ajh.21366.
7
10 years of progress in chronic myelogenous leukemia.慢性粒细胞白血病十年进展
J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. doi: 10.6004/jnccn.2012.0110.
8
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.达沙替尼治疗对伊马替尼耐药的慢性粒细胞白血病患者时BCR/ABL1融合基因和JAK2V617F突变均消失
J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145.
9
[Molecular targeting therapy for chronic myeloid leukemia].[慢性髓性白血病的分子靶向治疗]
Rinsho Ketsueki. 2007 Jan;48(1):46-55.
10
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].[慢性髓性白血病患者BCR-ABL酪氨酸激酶抑制剂的治疗药物管理]
Rinsho Ketsueki. 2013 Oct;54(10):1720-9.

引用本文的文献

1
A novel imatinib analogue inhibitor of chronic myeloid leukaemia: design, synthesis and characterization-explanation of its folded conformation.一种新型慢性髓性白血病伊马替尼类似物抑制剂：设计、合成及其折叠构象的表征解释
R Soc Open Sci. 2025 Jan 29;12(1):241654. doi: 10.1098/rsos.241654. eCollection 2025 Jan.
2
Discovery of a Cushing's syndrome protein kinase A mutant that biases signaling through type I AKAPs.发现一种库欣综合征蛋白激酶 A 突变体，该突变体通过 I 型 AKAP 偏向信号传导。
Sci Adv. 2024 Feb 23;10(8):eadl1258. doi: 10.1126/sciadv.adl1258. Epub 2024 Feb 21.
3
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Ph-like ALL 取代 Ph+ ALL 成为预后最差的亚型了吗？
Best Pract Res Clin Haematol. 2021 Dec;34(4):101331. doi: 10.1016/j.beha.2021.101331. Epub 2021 Oct 23.
4
Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations.慢性髓性白血病患者的分子、细胞遗传学和血液学分析以及两种新型易位的发现
Anal Cell Pathol (Amst). 2021 Aug 12;2021:4909012. doi: 10.1155/2021/4909012. eCollection 2021.
5
DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34 CD15 cells in early chronic-phase chronic myeloid leukemia.DNA 甲基化分析揭示了一种病理性特征，该特征导致早期慢性期慢性髓性白血病中 CD34 CD15 细胞的转录缺陷。
Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.
6
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.非 ABL 靶向抑制剂作为慢性髓性白血病的替代治疗策略。
Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1.
7
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.双蛋白激酶和核苷激酶调节剂用于合理设计多药理学。
Nat Commun. 2017 Nov 10;8(1):1420. doi: 10.1038/s41467-017-01582-5.
8
Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL B-Lineage Acute Lymphoblastic Leukemia.二氢青蒿素通过下调 MCL-1 表达增强 Navitoclax 对 BCR-ABL 阳性 B 细胞急性淋巴细胞白血病的敏感性。
Clin Cancer Res. 2017 Dec 15;23(24):7558-7568. doi: 10.1158/1078-0432.CCR-17-1231. Epub 2017 Oct 3.
9
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.整合转录组学数据与基于机制的系统药理学模型，用于虚拟药物联合试验。
ACS Chem Neurosci. 2018 Jan 17;9(1):118-129. doi: 10.1021/acschemneuro.7b00197. Epub 2017 Oct 6.
10
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.表皮生长因子受体酪氨酸激酶抑制剂用于治疗非小细胞肺癌的中枢神经系统转移：现状与未来
Transl Lung Cancer Res. 2016 Dec;5(6):563-578. doi: 10.21037/tlcr.2016.10.16.